The C-CRK gene, cellular homolog of the avian v-crk oncogene, encodes two alternatively spliced adaptor signaling proteins, CRKI (28 kDa) and CRKII (40 kDa). Both CRKI and CRKII have been shown to activate kinase signaling and anchorage-independent growth in vitro and CRKI transformed cells readily form tumors in nude mice. Affymetrix oligonucleotide arrays were used to analyse 86 lung adenocarcinomas and 10 uninvolved lung tissues. C-CRK mRNA expression was increased in more advanced (stage III versus stage I), larger (T 2-4 versus T 1 ), and poorly differentiated tumors and in tumors from patients demonstrating poor survival (P ¼ 0.00034). An overlapping series of 93 lung adenocarcinomas (64 stage I and 29 stage III) and 10 uninvolved lung specimens were measured for quantitative differences in CRKI and CRKII protein levels using 2-D PAGE. CRK protein spots were identified using mass spectrometry and 2-D Western blotting. A significant increase in levels of the CRKI oncoprotein and the phosphorylated isoform of CRKII was observed in tumors (Po0.05). No difference in protein level was evident between stages. Concordant with mRNA expression, CRKI and CRKII were increased in poorly differentiated tumors (Po0.05). CRK immunohistochemical analysis of tumor tissue arrays using the same tumor series also demonstrated increased abundance of nuclear and cytoplasmic CRK in more proliferative tumors (Po0.05). This study provides the first quantitative analysis of discrete CRKI and CRKII protein isoforms in human lung tumors and provides evidence that the C-CRK proto-oncogene may foment a more aggressive phenotype in lung cancers.
Introduction
Lung cancer is the most common cause of cancer death for both men and women, and existing 5-year survival rates of 12-15% have not improved (Fry et al., 1999; Landis et al., 1999) . Lung adenocarcinoma is habitually characterized by the development of metastases early in disease progression, often while tumors are incipient asymptomatic lesions. Recently, in an effort to mitigate the poor prognosis associated with this disease, we reported construction of an index, based on gene expression profiling, capable of predicting stage I tumors at high-risk for progression, therefore, identifying candidates for potential directed therapy . Furthermore, we have employed 2-D polyacrylamide gel electrophoresis (PAGE) to identify and quantitatively measure protein isoforms altered in lung adenocarcinomas Gharib et al., 2002) .
The C-CRK proto-oncogene encodes two alternatively spliced protein products, CRKI (28 kDa) and CRKII (40 kDa), belonging to the large CRK family of scaffolding proteins that participate in a variety of biological processes (Matsuda et al., 1992; Feller, 2001 ). C-CRK was identified from two distinct human CRK cDNAs, designated CRK-I and CRK-II, and cloned from embryonic human lung (Matsuda et al., 1992) . The human C-CRK gene was subsequently identified to share extensive amino-acid sequence with the v-crk oncogene, initially isolated from the chicken retrovirus CT-10 (Mayer et al., 1988) . Both the C-CRK and the vcrk oncogene harbor SH2 (Src homology 2) and SH3 (Src homology 3) sequences, domains shared with many molecules involved in signal transduction including ras, phospholipase C-g and nonreceptor-type signaling kinases. Cells transformed by v-crk were shown to have increased phosphotyrosine, despite an absence of intrinsic v-Crk catalytic activity (Mayer et al., 1988 (Mayer et al., , 1989 . Likewise, human CRK proteins also lack catalytic activity, but are critically important for signal propagation along multiple pathways. Previous studies have ascribed CRKI and CRKII's signaling activity to direct association with other signaling proteins including p 130CAS , C3G, JNK1, paxillin, and HPK1 (Tanaka et al., 1997; Dolfi et al., 1998; Klemke et al., 1998; Oehrl et al., 1998; Petit et al., 2000; Girardin and Yaniv, 2001) .
CRKI and CRKII are structural analogues, but have distinct biological activities (Matsuda et al., 1992) . Rat fibroblasts and COS7 cells overexpressing CRKI present altered morphology in soft agar and readily form tumors in nude mice, while cells overexpressing CRKII have no transforming activity (Matsuda et al., 1992) . Evidence from multiple model systems, however, has shown that increased CRKII activity promotes suppression of apoptosis, induces lamellipodia formation and cell spreading in migratory cells (Cheresh et al., 1999) , and encourages anchorage-independent growth (Klemke et al., 1998) .
Although prior studies have examined the effects of CRKI and CRKII expression in vitro, analysis of CRK levels in human primary tumors is limited. Nishihara et al. (2002) recently identified increased expression of CRKII in multiple tumor types including lung adenocarcinoma. The study did not delineate, however, between the levels of distinct CRKII isoforms or examine protein levels of the alternatively spliced oncoprotein product CRKI. We, therefore, investigated levels of C-CRK mRNA and protein isoforms using Affymetrix oligonucleotide arrays and quantitative 2-D PAGE. Increased levels of CRKI were observed in poorly differentiated, more invasive, and advancedstage tumors. Furthermore, mRNA levels were elevated in early-stage tumors at 'high-risk' for disease progression . CRKII expression was also increased in tumors and poor versus well-differentiated tumors. These results provide evidence that increased levels of the CRK proteins are associated with an aggressive phenotype, resulting in poor survival in lung adenocarcinomas.
Results
Increased C-CRK mRNA expression was detected in clinically aggressive lung adenocarcinomas
We analysed 86 lung adenocarcinomas (67 stage I and 19 stage III) and 10 uninvolved tissues for C-CRK mRNA expression using Affymetrix oligonucleotide arrays. The C-CRK oligonucleotide probe detected both C-CRK transcripts (C-CRKI and C-CRKII). No remarkable difference in expression was observed between tumor and uninvolved lung tissues; however, a significant increase (Po0.05) in mRNA expression was observed in advanced-stage (stage III versus stage I) and more invasive (T 2-4 versus T 1 ) tumors (Figure 1a ). An increase in C-CRK expression was also observed in high-risk (poorer survival) stage I tumors (Po0.05; Figure 1b ). High-risk stage I and III tumors expressed significantly more C-CRK mRNA than low-risk stage I and III tumors (Po0.01). No expression difference was seen between high-risk stage I and stage III tumors. Kaplan-Meier survival plots and univariate Cox proportional hazards regression methods indicated a significant correlation between mRNA expression and survival (P ¼ 0.006 and 0.00034, respectively). Increased expression was also identified in poorly versus well and moderately differentiated tumors (Po0.05; Figure 1c ).
Increased levels of CRKI and CRKII protein isoforms were detected in malignant lung tissues A series of 93 lung tumors, 76 of which (57 stage I and 19 stage III) were used in array analyses, was analysed for expression of CRK protein products using 2-D PAGE. Three individual CRK isoforms (CRKI, #2132; CRKII, #714, #707) were identified on 2-D gels using mass spectrometry and verified by Western blotting with the a-CRK, a-CRKII, and a-phospho-CRKII (Tyr221) antibodies (Figure 2b-d) . These spots were then matched to corresponding spots on 2-D gels from each tumor and uninvolved lung specimen analysed. An additional CRKI and CRKII isoform was visible by 2-D Western blotting ( Figure 2b) ; however, protein quantities were too small to allow quantification in individual silver-stained gels. To ascertain whether increased protein levels resulted primarily from transcriptional control, we analysed the correlation between protein isoform levels and mRNA expression in the same tumors using Spearman correlation coefficients utilizing data from oligonucleotide arrays and 2-D protein gels. A significant correlation was not observed, however, between the levels of mRNA and individual protein isoforms (#707, r ¼ 0.046; #714, r ¼ À0.043; #2132, r ¼ 0.0031). The positive expression rate (4normal mean þ 2 s.d.) was examined using all tumors from the mRNA and protein sets to determine the frequency of increased C-CRK expression in our tumor series ( Figure 3 ). The frequency of positive expression was found to vary between C-CRK mRNA and protein isoforms. C-CRK mRNA and protein spots #707, #714, and #2132 had positive expression rates of 14, 24.7, 7.5 and 29%, respectively. Positive expression of C-CRK mRNA, CRKII (#707), and CRKI (#2132) was absent from all uninvolved lung tissues; however, 10% (1/10) of uninvolved lung tissues had positive expression of CRKII (#714) (Figure 3 ). Quantitative analysis of CRK protein spots indicated increased levels of CRKI (#2132) and phosphorylated CRKII (#707) in tumors compared to uninvolved lung tissue (Po0.05; Figure 4a ). CRKI (#2132) and CRKII (#707) levels were also found to be increased in bronchial-derived (n ¼ 48) versus In concordance with C-CRK mRNA expression, all protein isoforms were found increased in poor versus well-differentiated tumors (Po0.05). Moderately differentiated tumors also demonstrated increased protein levels of both CRKII isoforms compared to welldifferentiated tumors (Po0.01; Figure 4b ). Additionally, phospho-CRKII levels were not elevated with respect to total CRK levels in well versus poorly differentiated tumors (P ¼ 0.338) or stage I versus stage III tumors (P ¼ 0.895). CRK protein isoforms were also examined for their correlation with survival; unlike C-CRK mRNA expression, however, the relation did not reach statistical significance.
Lung cancer cell lines were examined to ascertain the expression levels of CRK proteins in vitro. All five cell lines investigated (H460, A427, H1437, A549, and SKLU1) were found to express detectable amounts of CRKII (40 kDa) (data not shown). Moderate variability in CRKII levels was observed with a greater than fourfold difference in protein levels between the lowest (H460) and highest (A549) expressing cell lines. However, we observed no difference in CRK expression with respect to cell-line differentiation. CRKI (28 kDa) expression was only detected in the A549 cell line.
Immunohistochemical analysis identified increased CRK protein levels in highly proliferative tumors
Ninety lung adenocarcinomas from the oligonucleotide array and 2-D PAGE series were analysed for CRK protein expression in formalin-fixed paraffin-embedded tissue microarray sections using a-CRK and a-CRKII antibodies ( Figure 5 ). The a-CRK and a-CRKII antibodies exhibited commensurate staining in both the nucleus and cytoplasm of all samples. Staining with the a-CRKII antibody was observed in o5% of cells in uninvolved lung tissues (Figure 5a ). Discordant staining was observed within differentiation groups. Representative sections of well (Figure 5c ), moderate (Figure 5d ), and poorly differentiated (Figure 5e ) tumor morphology demonstrate CRKII protein levels within their respective differentiation groups. Analysis using Student's ttest did not indicate a statistically significant difference in CRK or CRKII staining intensity between tumor differentiation groups (data not shown). This discrepancy with the 2-D protein data most likely results from the inability to distinguish between individual protein isoforms by IHC and the difficulty of obtaining quantitative protein measurements with this technique. The relation between CRK tissue staining and survival using Kaplan-Meier analysis was also examined, but no correlation was observed (P ¼ 0.5).
The proliferation index, as determined using labeling with the MIB-1 antibody for the Ki-67 antigen, was used for demonstration of cell proliferation (G 1 , S, G 2 , and M phases) in 66 of the primary lung adenocarcinoma specimens ( Figure 5f ). As expected, Ki-67 antigen expression correlated strongly with tumor differentiation, with mean expression frequencies of 2.0% (well), 10.6% (moderate), and 31.0% (poor). Significant differences in Ki-67 expression were observed between all differentiation groups (well versus moderate, Po0.00001; moderate versus poor, P ¼ 0.0002; well versus poor, Po0.00001). C-CRK mRNA was strongly correlated (r ¼ 0.314; Po0.01) with cell proliferation in our series of tumors. CRK protein staining assessed using IHC also significantly correlated (r ¼ 0.24, Po0.05) with cell proliferation in lung adenocarcinomas. Individual protein spots and total CRK protein levels (2-D PAGE) were also assessed for their correlation with cell proliferation; however, no single isoform was independently correlated with Ki-67 nuclear expression (#707, r ¼ 0.04; #714, r ¼ 0.18; #2132, r ¼ 0.02; total CRK, r ¼ 0.21).
Discussion
As tumors become invasive and metastasize, they develop altered morphology and decreased avidity for Figure 5 Immunohistochemical analysis of CRKII expression in well, moderate and poorly differentiated lung adenocarcinomas. Paraffin sections of tissue microarrays were analysed using the a-CRKII antibody and counterstained with hematoxylin. (a) CRKII expression was observed in o5% of cells in uninvolved lung tissues. (b) A blocking peptide against the CRKII antibody eliminated all staining in a poorly differentiated tumor (same tumor as in Figure 5e ). Both cytoplasmic and nuclear staining (arrows) were observed in well (c), moderate (d) and poorly (e) differentiated tumors. (f) Ki-67 antigen staining in a highly proliferative lung adenocarcinoma. Original photographs were taken at magnification 200 Â their extracellular matrix. Concordantly, C-CRK has been shown to play a salient role in cytoskeletal reorganization, suppression of apoptosis, and loss of anchorage-dependent growth during epithelial cell migration (Klemke et al., 1998; Cho and Klemke, 2000; Lamorte et al., 2002) . The present study supports a similar role for C-CRK in lung adenocarcinoma. C-CRK mRNA was found to be overexpressed in tumors of advanced stage (stage III) and in a subset of stage I tumors. Stage III lung tumors are characterized by their increased size, invasiveness and regional metastatic activity, while stage I tumors are usually of smaller size and show no evidence of invasion (Hoffman et al., 2000) . Approximately 30-50% of stage I patients relapse (Williams et al., 1981; Naruke et al., 1988) , however, and we have previously shown that a subset demonstrates a high-risk expression pattern indicative of poorer survival . The finding that C-CRK expression is increased in stage III, high-risk stage I, and more proliferative tumors indicates that increased transcriptional activity of C-CRK may underlie the transition to a more aggressive phenotype.
Identification and quantitation of CRKII and CRKI protein isoforms in our series of lung cancers revealed that elevated mRNA expression is concomitant with an increase in protein levels. Two of three CRK isoforms (CRKI, #2132; CRKII, #707) analysed demonstrated increased levels in tumors compared with uninvolved lung, and concordant with C-CRK mRNA expression, all CRK isoforms were significantly increased in more poorly differentiated tumors. Loss of the differentiation characteristics of epithelial cells and acquisition of a more mesenchymal-like phenotype is associated with carcinoma progression (Thiery, 2002) . In general, certain phenotypic alterations precipitate this transition; they include activation of several receptor tyrosine kinases, loss of E-cadherin expression, and relocalization of b-catenin (Edelman et al., 1983; Frixen et al., 1991; Miller and McClay, 1997; Morali et al., 2000; Ciruna and Rossant, 2001) . Interestingly, Lamorte et al. (2002) have recently demonstrated that CRKII performs a critical role in promoting an epithelial-mesenchymallike transition in epithelial cells. Stable overexpression of CRKII activated downstream effectors Rac1 and Rap and promoted spreading of MDCK (normal kidney) cells (Lamorte et al., 2002) . Furthermore, CRKII stimulated the breakdown of epithelial adherens junction formation by inhibiting membrane accumulation of E-cadherin and b-catenin and promoted cell dispersal in moderately differentiated breast cancer cell lines (Lamorte et al., 2002) . Therefore, our data demonstrating increased expression of C-CRK in poorly differentiated tumors suggests that CRK may be involved in promoting an epithelial-mesenchymal-like transition in lung adenocarcinomas.
Protein isoform expression in normal and tumor cells is regulated by gene transcription and a multitude of post-transcriptional and post-translational modifications, including phosphorylation, glycosylation, protein degradation, and peptide cleavage. Both CRKI and CRKII have known phosphorylation sites. CRKII (spot #707) and the CRKI oncoprotein (spot #2132) were increased in a large percentage of lung tumors ( Figure 3) ; however, C-CRK mRNA overexpression was less frequently observed than increased CRK protein levels and was primarily increased in stage III and poor prognosis stage I tumors. Additionally, C-CRK mRNA expression was not found to correlate with individual protein spot levels, indicating the additional mechanisms likely regulate CRK expression in lung adenocarcinomas. CRKII has been shown to participate in MAP kinase signaling pathways and is regulated by mitogenic growth factor receptors (York et al., 1998) . Both IGF1 and EGF treatment have been shown to stimulate phosphorylation of CrkII in vitro and may, therefore, influence CRKII protein levels and activity (Fajardo et al., 1993; Beitner-Johnson and LeRoith, 1995) . It is presumable then that increased levels of CRKI and CRKII isoforms could be regulated by both increased C-CRK transcription and enhanced mitogenic growth signaling in lung adenocarcinomas.
The data presented here and in previous reports defining C-CRK's growth-promoting properties provide evidence for the involvement of CRKI and CRKII in the development and dissemination of lung adenocarcinomas. Moreover, increases in C-CRK mRNA and protein expression in progressively poorer differentiated tissues imply a possible role for CRK in transitioning from early to more advanced stages in lung tumors. Future analyses examining the specific function that CRK plays in lung cancers, and the molecular pathways involved, may reveal novel targets for therapeutic intervention in the treatment of this deadly disease.
Materials and methods

Tissue procurement and preparation
Patients undergoing resection for stages I and III lung adenocarcinoma at the University of Michigan Medical Center between May 1991 and July 2000 were evaluated for inclusion in this study. Consent was obtained from patients and the project was approved by the University of Michigan Institutional Review Board. Tumor tissues and adjacent uninvolved (normal) lung tissue were acquired after resection and placed into Dulbecco's modified Eagle's medium for transport to the laboratory (Life Technologies, Gaithersburg, PA, USA). A portion of each tissue was embedded in OCT compound (Miles Scientific, Naperville, IL, USA), frozen in isopentane, and stored at À801C. The remaining tissue was frozen in liquid nitrogen and stored at À801C. Hematoxylin and eosin (H&E)-stained sections (5 mm), prepared from samples to be utilized for RNA isolation, were examined by study pathologists (TJG and DGT) and compared to H&E-stained paraffin blocks of the same tumors. Specimens were excluded based on unclear or mixed histology, o70% tumor cellularity, previous patient tumor history, extensive lymphocytic infiltration or fibrosis, or previous patient chemotherapy or radiotherapy. Tumors were staged according to the TNM tumor classification system (primary tumor (T), nodal status (N), and distant metastases (M)). T 1 tumors were defined as p3.0 cm at greatest dimension, surrounded by visceral pleura and without evidence of invasion proximal to a lobar bronchus at bronchoscopy. T 2-4 tumors were X3.0 cm or any size with invasion into major anatomical structures including the mediastinum, pericardium, esophagus, carina, diaphragm, or vertebral body. Stage I tumors are malignancies of any size without direct extension into the chest wall, diaphragm, mediastinal pleura, or pericardium. Tumors must also be within the lobar bronchus or at least 2 cm below the carina. Stage III tumors can be of any T-status with local or distant nodal metastases. No tumors with detectable distant metastases (stage IV) at resection were used in this study. The World Health Organization classification of lung adenocarcinomas includes acinar, papillary, bronchoalveolar, and solid, indicating substantial heterogeneity between lung adenocarcinomas (Colby et al., 1995) . For the purpose of this project, tissues were divided into two categories: bronchial-derived, if tumors demonstrated more invasive characteristics with architectural destruction; or bronchoalveolar, if tumors exhibited preserved lung architecture. Tumors designated as 'high-risk' exhibited expression profiles portending a poor prognosis . (43), and poorly differentiated (20). Two contiguous 2-mm 3 samples were removed for RNA and protein isolation. Total cellular RNA was isolated using Trisol reagent (Life Technologies) and subjected to further purification using RNeasy columns (Qiagen, Valencia, CA, USA). In all, 5 mg of sample RNA was used as a template. All protocols used for mRNA reverse transcriptase, second-strand synthesis, production of cDNA and RNA amplification, hybridization, and washing conditions for the HUGeneFL (aka HU6800) oligonucleotide arrays were provided by the manufacturer (Affymetrix, Santa Clara, CA, USA) and performed as previously described (Giordano et al., 2001) . Methods on C-CRK mRNA level quantification, data normalization, and array validation using Northern blots were as reported for this data set (Giordano et al., 2001; Beer et al., 2002) .
RNA isolation and oligonucleotide microarray analysis
2-D PAGE, spot detection and quantification
2-D PAGE was performed as previously described . Briefly, 93 tumor and 10 uninvolved protein samples were solubilized in standard lysis buffer and sample volumes of between 15 and 30 ml were applied to isoelectric focusing gels containing 50 ml of ampholytes (pH 3.5-10; Pharmacia/LKB, Piscataway, NJ, USA) per milliliter. Firstdimensional separation was performed at 700 V for 16 h, and then at 1000 V for 2 h at room temperature. Second-dimensional separation was achieved using an 18 Â 18 cm 2 gel containing an acrylamide gradient of 11.4-14 g/dl. Protein spots were visualized by a photochemical silver-based staining technique. Each gel was scanned and spots were detected using Bio Image Visage System software (Bio Image, Ann Arbor, MI, USA). Each gel generated 1600-2200 detectable spots. Well-defined spots were chosen to obtain quantitative measurements and then matched to a 'master' gel to allow for the comparison of identical polypeptides in all gels (Kuick et al., 1991; Gharib et al., 2002) . Each of the quantitated spots was then mathematically adjusted in relation to the reference spots (Kuick et al., 1987) . Tumors were stratified into the following categories for protein data analyses: stage I (64), stage III (29), well differentiated (22), moderately differentiated (47), and poorly differentiated (23).
Statistical analyses
The transform x-log(1 þ x) was applied to all expressed protein measurements. Student's t-test was used for comparing protein and mRNA expression in lung adenocarcinoma versus uninvolved lung. An F-test was used to compare values of other clinical-pathological variables by constructing background adjusted protein spot size quantification. A probability (P) level o0.05 (two-sided) was considered statistically significant. Potential associations between protein spot and gene expression were determined using Spearman correlation coefficients for individual genes and proteins in the same samples. Survival time was calculated from the date of surgery until the date of lung cancer-related death or the last available follow-up. Univariate Cox proportional hazards regression methods and Kaplan-Meier survival plots were used to identify genes and proteins associated with variability in survival.
Mass spectrometry and 2-D Western blotting
Protein spots of interest were removed from preparative 2-D gels prepared with extracts from A549 cell lysates (ATCC), as previously described . Identification of proteins was performed by trypsin digestion followed by nanoflow capillary liquid chromatography coupled with electrospray tandem mass spectrometry (ESI MS/MS) in a Q-TOF micro (Micromass, Manchester, UK). MS/MS spectra were automatically processed and searched against a database using ProteinLynx Global SERVER (www.micromass.co.uk).
Protein separation and 2-D Western blotting were as described previously . Individual membranes were incubated with a-CRKII (Santa Cruz Biotechnology, Santa Cruz, CA, USA), a-CRK (BD Transduction Laboratories, Lexington, KY, USA), and a-phospho-CRKII (Tyr221) (Cell Signaling Inc., Beverly, MA, USA) antibodies at 1 : 500 dilutions. Following additional washes, membranes were incubated with a secondary antibody conjugated with horseradish peroxidase (HRP) at a 1 : 5000 dilution for 1 h, then washed and incubated for 1 min with enhanced chemiluminescence (ECL) (Pierce, Rockford, IL, USA), and exposed to film (Amersham, Piscataway, NJ, USA).
Human lung cancer cell lines H460, A427, H1437, and SKLU1 were utilized for one-dimensional Western blotting. Cells were cultured in DME and supplemented with 10% FBS and a 1% solution of penicillin, streptomycin, and fungizone (Gibco BRL, Life Technologies, Gaithersburg, MD, USA). Western blotting was performed as previously described (Hughes et al., 1997) . Whole cell protein extracts were prepared using NP-40 lysis buffer (0.2% Igepal, 100 mm Tris-HCL at pH 8.0, 200 mm NaCl, and 0.01% SDS). a-CRK (BD Transduction Laboratories), a-CRKII (Santa Cruz Biotechnology), and a-phospho-CRKII (Tyr221) (Cell Signaling) were used at a dilution of 1 : 5000 for CRK protein detection.
Immunohistochemistry
Tumor diagnoses and construction of tissue microarray blocks were performed as previously described (Kononen et al., 1998) . Deparaffinized sections were microwave-pretreated in citric acid for antigen retrieval. Sections were then incubated with 1% hydrogen peroxide for 1 h to quench endogenous peroxidase activity. Following blocking, sections were incubated with a-CRKII (1 : 200) (BD Transduction Laboratories) or a-CRK (1 : 200) (Santa Cruz Biotechnology) antibodies overnight at 41C. Specificity of staining was controlled using a blocking peptide for a-CRKII. The a-CRK antibody detects all protein isoforms and a-CRKII is CRKII specific. Immunocomplexing was visualized by the enzyme-bridge technique using a Vector ABC peroxidase kit (Vector Laboratories, Burlingame, CA, USA). Sections were counterstained with hematoxylin. Sections were analysed and delineated using the staining criteria: weak, strong, or absence of staining.
MIB-1 (1 : 100) (DAKO, Carpinteria, CA, USA) was used to analyse nuclear expression of the Ki-67 cell proliferation antigen in 66 tumors examined by both oligonucleotide array and 2-D protein analyses. The proliferative index of each tumor was determined by counting 41000 nuclei from each tumor and determining the percentage of labeled cells to total cell number. The data were then compared to variables including C-CRK mRNA and protein levels and tumor differentiation.
